Lexicon Pharmaceuticals, Inc. (LXRX) vs OmniAb, Inc. (OABI)
- Lexicon Pharmaceuticals, Inc. LXRX 1.52 −7.88%
- OmniAb, Inc. OABI 4.59 −2.96%
Lexicon Pharmaceuticals, Inc. and OmniAb, Inc. are both Biotechnology companies. Lexicon Pharmaceuticals, Inc. and OmniAb, Inc. are of similar size ($734.2M and $687.7M). OmniAb, Inc. grew revenue faster over the last twelve months: 67.0% against −29.0%. OmniAb, Inc. has the higher net margin (−115.1% vs −147.4%) and the higher return on invested capital (−14.5% vs −96.4%). Across the 17 metrics below, OmniAb, Inc. leads on 12 and Lexicon Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | LXRX | OABI | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.14% | 98.28% | 65.16% |
| Operating margin | (131.43%) | (125.78%) | 0.00% |
| Net margin | (147.38%) | (115.12%) | 0.00% |
| Free cash flow margin | (156.71%) | (47.17%) | 0.00% |
| Return on equity | (40.21%) | (16.95%) | (56.36%) |
| Return on assets | (25.70%) | (15.11%) | (48.04%) |
| Return on invested capital | (96.36%) | (14.52%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack